This is an observational trial designed to assess prospectively the adherence rate to AIs among women with invasive breast cancer (stages I-III) currently receiving AI adjuvant therapy after standard local and systemic therapy. We will study adherence by administrating the 8-item Morisky Medication Adherence Scale (MMAS - 8).
Women with breast cancer seen at the Texas Tech Physicians Breast Care Center will be recruited during their routine follow-up visit with their medical oncologist. Post - menopausal women with histologically confirmed hormonal positive (ER and/or PR) invasive breast cancer stages I - III with no evidence of metastatic disease (M0). Patients must be on one of AI (steroidal or non-steroidal). Patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery. Patient must be able to complete a demographic and the MMAS - 8 questionnaires in English or Spanish.
Post - menopausal women with histologically confirmed hormonal positive (ER and/or PR) invasive breast cancer stages I - III with no evidence of metastatic disease (M0). Patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery. Patient must be on one of AI (steroidal or non-steroidal). Patient must be able to complete a demographic and the MMAS - 8 questionnaires in English or Spanish
